MX2015008329A - Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. - Google Patents
Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.Info
- Publication number
- MX2015008329A MX2015008329A MX2015008329A MX2015008329A MX2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A MX 2015008329 A MX2015008329 A MX 2015008329A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion partners
- listerial
- expression
- preparation
- methods
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 3
- 108010076504 Protein Sorting Signals Proteins 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000028327 secretion Effects 0.000 abstract 2
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 241000607479 Yersinia pestis Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000172 cytosol Anatomy 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 125000001165 hydrophobic group Chemical group 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746237P | 2012-12-27 | 2012-12-27 | |
| US201361780744P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/078119 WO2014106123A1 (en) | 2012-12-27 | 2013-12-27 | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015008329A true MX2015008329A (es) | 2016-03-01 |
Family
ID=51017446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008329A MX2015008329A (es) | 2012-12-27 | 2013-12-27 | Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9663557B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2938627B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016503655A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102160322B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104955835B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2013370210B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015015076A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2888727A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201590397A8 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015008329A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201502792TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014106123A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| ES2741730T3 (es) | 2008-05-19 | 2020-02-12 | Advaxis Inc | Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico |
| US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| US9226958B2 (en) | 2010-10-01 | 2016-01-05 | University Of Georgia Research Foundation, Inc. | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| AU2012229218B2 (en) | 2011-03-11 | 2017-03-02 | Advaxis, Inc. | Listeria-based adjuvants |
| HK1205944A1 (en) | 2012-03-12 | 2015-12-31 | 阿德瓦希斯公司 | Suppressor cell function inhibition following listeria vaccine treatment |
| EP3193921A4 (en) | 2014-07-18 | 2018-04-25 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| WO2016061115A1 (en) | 2014-10-13 | 2016-04-21 | Providence Health & Services-Oregon D/B/A Providence Portland Medical Center | Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof |
| JP6895380B2 (ja) * | 2015-02-06 | 2021-06-30 | ナショナル ユニバーシティ オブ シンガポール | 治療免疫細胞の有効性を改良するための方法 |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| SG11201708360TA (en) * | 2015-04-13 | 2017-11-29 | Aduro Biotech Inc | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
| HK1250731A1 (zh) * | 2015-04-13 | 2019-01-11 | 艾杜罗生物科技公司 | 用於治疗癌症的免疫原性融合蛋白 |
| WO2016184860A1 (en) * | 2015-05-18 | 2016-11-24 | Universita' Degli Studi Di Trento | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
| EP3389630B1 (en) | 2015-12-16 | 2023-11-08 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| CN109475570B (zh) * | 2016-03-18 | 2022-04-01 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| CN118562882B (zh) | 2016-11-22 | 2025-08-08 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| AU2018336988B2 (en) | 2017-09-19 | 2023-06-22 | Advaxis, Inc. | Compositions and methods for lyophilization of bacteria or Listeria strains |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| CN112074737A (zh) | 2018-03-09 | 2020-12-11 | 阿德瓦希斯公司 | 用于评估李斯特菌菌株的减毒和感染性的组合物和方法 |
| EP3536706A1 (en) | 2018-03-09 | 2019-09-11 | BiOMVis Srl | Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof |
| EP3785029A1 (en) | 2018-04-27 | 2021-03-03 | Advaxis, Inc. | Compositions and methods for evaluating potency of listeria-based immunotherapeutics |
| CN110408634B (zh) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
| AU2019275076B2 (en) | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| EP3725371A1 (en) | 2019-04-18 | 2020-10-21 | BiOMVis Srl | Method for the production of outer membrane vesicles and immunogenic compositions thereof |
| CN110499324A (zh) * | 2019-09-02 | 2019-11-26 | 中生康元生物科技(北京)有限公司 | 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法 |
| US20240093318A1 (en) | 2020-06-23 | 2024-03-21 | The Regents Of The University Of Colorado, A Body Corporate | Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| US5856457A (en) | 1991-03-29 | 1999-01-05 | Genentech, Inc. | Nucleic acids encoding a human IL-8 receptor |
| IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
| US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| AU6501296A (en) | 1995-07-21 | 1997-02-18 | General Hospital Corporation, The | Method and apparatus of enhancing the delivery of a pharmaceutical formulation |
| US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| AU2001255196A1 (en) * | 2000-03-29 | 2001-10-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| CA2460014A1 (en) | 2000-09-21 | 2002-03-28 | The Regents Of The University Of California | Spas-1 cancer antigen |
| JP2005527240A (ja) * | 2002-05-29 | 2005-09-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 弱毒リステリア種とこれを使用する方法 |
| AU2003259109A1 (en) | 2002-07-12 | 2004-02-02 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| AU2004281834A1 (en) | 2003-10-15 | 2005-04-28 | Cerus Corporation | Listeria-based EphA2 vaccines |
| US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| US7858097B2 (en) * | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
| WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| DK1991263T3 (en) | 2006-03-01 | 2015-03-30 | Aduro Biotech | Prepared listeria and methods of use thereof |
| US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
| US20080124354A1 (en) | 2006-07-10 | 2008-05-29 | Yvonne Paterson | Methods for administering tumor vaccines |
| JP2010534058A (ja) * | 2007-04-16 | 2010-11-04 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗生物質耐性のないリステリア菌およびその構築および使用方法 |
| WO2009143085A1 (en) | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comprising prfa*mutant listeria and methods of use thereof |
| GB201010389D0 (en) | 2010-06-21 | 2010-08-04 | Ist Superiore Sanita | Antibody derivatives |
| EP2640842B1 (en) | 2010-11-17 | 2018-05-30 | Aduro Biotech, Inc. | Methods and compositions for inducing an immune response to egfrviii |
| AU2012229218B2 (en) | 2011-03-11 | 2017-03-02 | Advaxis, Inc. | Listeria-based adjuvants |
| HK1205944A1 (en) | 2012-03-12 | 2015-12-31 | 阿德瓦希斯公司 | Suppressor cell function inhibition following listeria vaccine treatment |
-
2013
- 2013-12-27 EA EA201590397A patent/EA201590397A8/ru unknown
- 2013-12-27 EP EP13869448.4A patent/EP2938627B1/en not_active Not-in-force
- 2013-12-27 US US14/142,614 patent/US9663557B2/en not_active Expired - Fee Related
- 2013-12-27 CA CA2888727A patent/CA2888727A1/en not_active Abandoned
- 2013-12-27 WO PCT/US2013/078119 patent/WO2014106123A1/en not_active Ceased
- 2013-12-27 AU AU2013370210A patent/AU2013370210B2/en not_active Ceased
- 2013-12-27 SG SG11201502792TA patent/SG11201502792TA/en unknown
- 2013-12-27 KR KR1020157015490A patent/KR102160322B1/ko not_active Expired - Fee Related
- 2013-12-27 MX MX2015008329A patent/MX2015008329A/es unknown
- 2013-12-27 BR BR112015015076A patent/BR112015015076A2/pt active Search and Examination
- 2013-12-27 SG SG10201700916SA patent/SG10201700916SA/en unknown
- 2013-12-27 CN CN201380068458.4A patent/CN104955835B/zh not_active Expired - Fee Related
- 2013-12-27 JP JP2015550820A patent/JP2016503655A/ja active Pending
-
2017
- 2017-05-18 US US15/599,441 patent/US20170253637A1/en not_active Abandoned
-
2018
- 2018-04-06 JP JP2018074066A patent/JP6671408B2/ja not_active Expired - Fee Related
- 2018-05-21 AU AU2018203555A patent/AU2018203555A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018135355A (ja) | 2018-08-30 |
| JP2016503655A (ja) | 2016-02-08 |
| WO2014106123A1 (en) | 2014-07-03 |
| SG11201502792TA (en) | 2015-05-28 |
| AU2013370210B2 (en) | 2018-06-14 |
| HK1215260A1 (zh) | 2016-08-19 |
| US9663557B2 (en) | 2017-05-30 |
| EP2938627A1 (en) | 2015-11-04 |
| WO2014106123A8 (en) | 2016-06-16 |
| AU2018203555A1 (en) | 2018-06-07 |
| CA2888727A1 (en) | 2014-07-03 |
| BR112015015076A2 (pt) | 2018-10-30 |
| AU2013370210A1 (en) | 2015-06-18 |
| JP6671408B2 (ja) | 2020-03-25 |
| SG10201700916SA (en) | 2017-03-30 |
| KR102160322B1 (ko) | 2020-09-25 |
| EA201590397A1 (ru) | 2016-02-29 |
| US20140186387A1 (en) | 2014-07-03 |
| EP2938627A4 (en) | 2016-12-14 |
| AU2013370210A8 (en) | 2016-06-23 |
| EA201590397A8 (ru) | 2016-08-31 |
| EP2938627B1 (en) | 2019-03-20 |
| KR20150099738A (ko) | 2015-09-01 |
| CN104955835A (zh) | 2015-09-30 |
| US20170253637A1 (en) | 2017-09-07 |
| CN104955835B (zh) | 2020-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015008329A (es) | Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos. | |
| WO2009130618A3 (en) | Flagellin polypeptide vaccines | |
| WO2011140284A3 (en) | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses | |
| MY173004A (en) | Mycobacterial antigen vaccine | |
| EP2772265A3 (en) | Recombinant HCMV and RHCMV vectors and uses thereof | |
| NZ753307A (en) | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof | |
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| WO2013151706A3 (en) | Subunit vaccine delivery platform for robust humoral and cellular immune responses | |
| NZ745324A (en) | Vaccines and vaccine components for inhibition of microbial cells | |
| EA201791806A1 (ru) | Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов | |
| MX2014009845A (es) | Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos. | |
| MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
| MX2017000838A (es) | Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas. | |
| MX2017015404A (es) | Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas. | |
| WO2020065349A8 (en) | Vaccines and methods | |
| MY202196A (en) | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses | |
| Badell et al. | Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells | |
| NZ725212A (en) | Group a streptococcus vaccine | |
| PH12017502080A1 (en) | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same | |
| NZ760008A (en) | Uti fusion proteins | |
| Wang et al. | Immunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B | |
| Sharma et al. | Mycobacterium indicus pranii protein MIP_05962 induces Th1 cell mediated immune response in mice | |
| IN2013CN01528A (cg-RX-API-DMAC7.html) | ||
| EP2488197A4 (en) | TH1 / TH2 POLARIZING VACCINES | |
| WO2006102901A3 (en) | Immunogenic egfr peptides comprising foreign t cell stimulating epitope |